NCT06678035

Brief Summary

This study aims to Primary Aims: Verify the predictability of the PLIS at admission in predicting major clinical outcomes including:

  • ICU mortality (or discharge) and time to death (or discharge)
  • Escalation of ventilatory support antibiotic therapy or supportive medications (inotropes, steroids, sedation, neuromuscular blockers). Secondary Aims:
  • Determine the correlation between initial PLIS and the degree of disease severity (as evaluated per SOFA and APACHE II scores)
  • Determine the correlation between initial PLIS and partial pressure of oxygen in arterial blood (PaO2) to Fraction of inspired oxygen (FiO2): PaO2/FiO2
  • Explore the potential association between the type of ventilatory support, ventilatory settings and PLIS at different time points.
  • Verify whether the site of consolidation (anterior vs. posterior lung zones) can reliably predict mortality in in ALI patients.
  • Determine the correlation between the PLIS score and the degree of ALI as quantified by CT of the chest (whenever a CT study is available) at the time of admission.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
72

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2024

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 5, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

November 7, 2024

Completed
13 days until next milestone

Study Start

First participant enrolled

November 20, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2025

Completed
Last Updated

November 7, 2024

Status Verified

October 1, 2024

Enrollment Period

11 months

First QC Date

October 5, 2024

Last Update Submit

November 5, 2024

Conditions

Keywords

LUSAcute respiratory failureCritically-ill patients

Outcome Measures

Primary Outcomes (2)

  • ICU Mortality

    Percentage of patients who will die during their ICU admission

    60 days

  • Time to death/discharge

    Number of days until the patient dies inside the ICU or becomes discharged from ICU

    60 days

Secondary Outcomes (3)

  • Need for Therapy escalation: Ventilatory Support

    60 days

  • Need for Therapy Escalation: Ventilatory seetings

    60 days

  • Need for Therapy Escalation: Medications

    60 days

Eligibility Criteria

Age18 Days+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who are more than 18 years in repiratory failure in ICU and use of chest us in supine or semisupine position

You may qualify if:

  • Age is or more than 18 years old.
  • Admission to ICU in the first24 hours at time of recruitment to the study.
  • Patients in respiratory failure \[PaO2 is less then 60 % mmHg\]

You may not qualify if:

  • Co- existing chronic lung disease, pathology of which is known display abnormalities on US examination (interstitial lung diseases, bronchiectasis).
  • Large pneumothorax or massive pleural effusion causing significant collapse and precluding proper visualization of underlying lung.
  • Conditions that may interfere with lung ultrasound quality or probe contact such as marked obesity, severe chest wall deformities, burns or wounds.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Marchioni A, Castaniere I, Tonelli R, Fantini R, Fontana M, Tabbi L, Viani A, Giaroni F, Ruggieri V, Cerri S, Clini E. Ultrasound-assessed diaphragmatic impairment is a predictor of outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease undergoing noninvasive ventilation. Crit Care. 2018 Apr 27;22(1):109. doi: 10.1186/s13054-018-2033-x.

    PMID: 29703214BACKGROUND
  • Biasucci DG, Buonsenso D, Piano A, Bonadia N, Vargas J, Settanni D, Bocci MG, Grieco DL, Carnicelli A, Scoppettuolo G, Eleuteri D, DE Pascale G, Pennisi MA, Franceschi F, Antonelli M; Gemelli Against COVID-19 Group. Lung ultrasound predicts non-invasive ventilation outcome in COVID-19 acute respiratory failure: a pilot study. Minerva Anestesiol. 2021 Sep;87(9):1006-1016. doi: 10.23736/S0375-9393.21.15188-0. Epub 2021 Jul 14.

    PMID: 34263580BACKGROUND

Related Links

Central Study Contacts

Mona Zakria Hassab Elnabi, resident doctor

CONTACT

Hend Mohamed Sayed, lecturer

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor Principal investigator

Study Record Dates

First Submitted

October 5, 2024

First Posted

November 7, 2024

Study Start

November 20, 2024

Primary Completion

October 1, 2025

Study Completion

October 1, 2025

Last Updated

November 7, 2024

Record last verified: 2024-10